Connected AI Podcast: Donal O'Shea of Deciphex on improving pathology services with AI
The Connected AI Podcast, which is brought to you in association with Expleo, aims to cut through the hype and get to the heart of AI for business, with expert guests offering their advice, and the hosts giving their take on big developments in the space.
In the latest episode we're talking to Donal O'Shea, founder and chief executive of Deciphex. Donal talks to us about the use of AI to enhance pathology services
In addition, Charlie and Elaine discuss how people are using AI as an emotional support, how Cursor experienced the limitations for itself when the programming tool's own AI support bot hallucinated a policy limitation that doesn't exist, OpenAI's bid for Windsurf, and how films made with AI can win Oscars. Finally, they also look at Business Insider founder Henry Blodget's recent blogpost in which he admitted hitting on an AI employee he created.
The Connected AI Podcast. You won't want to miss it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Post
3 days ago
- Business Post
Andrew Ross: FBD's half-year results show resilience despite severe weather hit
Business Post subscribers can read: • How a surge in claims from Storm Éowyn cost FBD more in January than the whole of last year's storms combined. • Why higher cover levels and loyal customers, not just price hikes, drove premium growth. • What US tariffs and deglobalisation could mean for Ireland's insurers.
Business Post
3 days ago
- Business Post
US fund Apollo seal major deal for Irish firm Alchelyst
Business Post subscribers can read: • Details of Apollo and Motive Partners deal for Alchelyst • Who are the founders behind Alchelyst • What notable Irish investors have backed the company in recent years
Business Post
6 days ago
- Business Post
From Nasdaq to the Áras? Gareth Sheridan on Nutriband, a ‘lost generation' and his presidential bid
Business Post subscribers can read: • Why he has decided to enter the race and what the Nutriband board and investors have had to say about the move • How building a $74m Nasdaq-listed company shaped his vision for Ireland's future • The behind-the-scenes battle to get on the presidential ballot — and the councillor votes he claims to have secured • How he deals with the criticism, scrutiny and sometimes even abuse he and his family faces 'You can call me anything so long as you don't describe me as a pharma tycoon,' says Gareth Sheridan laughing as he pulls up a ...
